India Moves to Cut Prices of 137 Cancer Drugs by Up to 70%
A cap on distribution and retail margins takes effect on November 9, building on a 2019 scheme for 42 medicines.
Photo: Jorge Royan / CC BY-SA 3.0 via Wikimedia Commons
India's drug pricing regulator has moved to make dozens of cancer medicines cheaper. The National Pharmaceutical Pricing Authority (NPPA) announced on October 17 that it is rationalising trade margins on 137 anti-cancer drugs, with revised prices taking effect on November 9.
What is changing
The step targets what the government calls excessive margins in the distribution and retail chain, rather than the manufacturers' own prices. According to the announcement, the maximum retail price of the covered drugs could fall by up to 70%.
Other Indian outlets report that the margin is capped at 30% and that the list includes widely used immunotherapy and targeted-therapy medicines. Those details come from press coverage rather than the broadcaster's short report, so treat them as reported rather than official.
- 137 non-scheduled anti-cancer drugs are covered.
- Up to 70% is the possible fall in retail prices; the real cut will vary drug by drug.
- November 9 is when the new prices apply.
- State drug controllers are responsible for enforcement, and patients can check revised prices through the government's Pharma Sahi Daam app or the NPPA website.
Why it matters
Cancer treatment is a major cause of medical debt in India, where much healthcare spending is paid out of pocket. The measure builds on a 2019 pilot that capped margins on 42 anti-cancer drugs and, according to the announcement, cut the maximum retail price of 526 brands by up to 90%.
Caveats
"Up to 70%" is an upper bound. Drugs that are already priced below the new ceiling would not become cheaper, and how much a given patient saves will depend on the medicine and the brand. Real-world results will only be clear once the new prices reach pharmacies and hospitals next month.
